GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INZ-701 overview
INZ-701 is under development for the treatment of rare genetic diseases of ENPP1 deficiency (generalized arterial calcification infancy (GACI) and autosomal recessive hypophosphatemic rickets type II (ARHR2), rare genetic diseases of ABCC6 Deficiency (pseudoxanthoma elasticum or PXE), calciphylaxis and diseases of neointimal proliferation. It is administered through subcutaneous route.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Inozyme Pharma overview
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company that develops novel therapeutics for the treatment of rare genetic diseases of ENPP1, ABCC6 deficiencies and impacting the vasculature, soft tissue and skeleton. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of INZ-701’s drug-specific PTSR and LoA scores, buy the report here.
